Quintijn Bonnez: How ADAMTS13 Conformation May Predict Early Relapse and Guide Pre-Emptive Therapy
Quintijn Bonnez, Early-Career Board Member at Belgian Society on Thrombosis and Haemostasis, shared a post on LinkedIn about a recent article he and Karen Vanhoorelbeke co-authored, published in Belgian Journal of Hematology, adding:
“Have you already received your copy ?
Excited to see our Hematology review covered on the latest edition of the Belgian Journal of Hematology.
In this review, the evidence for open ADAMTS13 as a highly specific biomarker for both acute and subclinical iTTP was summarized. Beyond its diagnostic value, we highlighted how ADAMTS13 conformation may contribute to early relapse risk prediction and help guide pre-emptive therapeutic interventions.
Key messages for clinical practice:
- ADAMTS13 conformation adds diagnostic value beyond testing Enzyme activity.
- Distinct, open ADAMTS13 is characteristic for iTTP.
- Closed ADAMTS13 is preserved in healthy individuals and non-iTTP clinical conditions.
This exciting work continues to bridge fundamental protein Biology with clinical decision-making, bringing us one step closer to improved diagnosis and patient monitoring.”
Title: Distinct open ADAMTS13 for diagnosing and monitoring acute and subclinical immune-mediated thrombotic thrombocytopenic purpura
Authors: Quintijn Bonnez, Karen Vanhoorelbeke
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 14:32Kenneth Nollet: Building the Future of Transfusion Laboratory Science
-
Aug 21, 2026, 14:14Tareq Abadl: A Positive Antibody Screen is Not The Diagnosis
-
Aug 21, 2026, 14:08Katrina Snow։ Transfusion Trends and Quality Improvement in Sickle Cell Disease
-
Aug 21, 2026, 14:00Rucha Patil: The Power of Point-of-Care Testing in Hemostasis
-
Aug 21, 2026, 13:56Sarah Kowalski։ Supporting the Next Generation of Transfusion Laboratory Scientists
-
Aug 21, 2026, 13:51Join EHC 2026 Annual Conference
-
Aug 21, 2026, 12:57David McIntosh: Why Do Blood Supplies Still Fall Short?
-
Aug 21, 2026, 12:48Joshua Penrod: 35 Years of Progress in Plasma Safety
-
Aug 21, 2026, 12:42Moustafa Abdou: Diagnosis and Management of Pyruvate Kinase Deficiency